Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Small Cell Lung Carcinoma 1Sexually Transmitted Diseases, Viral 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 35pembrolizumab 29Radiotherapy 26Cetuximab 26Docetaxel 17Paclitaxel 13Fluorouracil 13Cyclophosphamide 12fludarabine 11Radiotherapy, Intensity-Modulated 11Nivolumab 10Carboplatin 9atezolizumab 7Radiation 7Gemcitabine 7Erlotinib Hydrochloride 7Bortezomib 7fludarabine phosphate 6Pemetrexed 5Interleukin-2 5Radiosurgery 4Everolimus 4Drug Therapy 4Azacitidine 4olaparib 3motexafin gadolinium 3durvalumab 3cemiplimab 3Trastuzumab 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Head and Neck Neoplasms × detox adjuvant × Clear all
NCT01493154 2018-11-23

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
2 enrolled
Head & Neck

Head and Neck Neoplasms, Sexually Transmitted Diseases, Viral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡